The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy - Jimenez-Fonseca, P.; Foy, V.; Raby, S.; Carmona-Bayonas, A.; Macía-Rivas, L.; Arrazubi, V.; Cacho Lavin, D.; Hernandez San Gil, R.; Custodio, A.; Cano, J.M.; Fernández Montes, A.; Mirallas, O.; et al. (Therapeutic Advances in Medical Oncology, 2023)